The short version of Nicotinamide mononucleotide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-25. Anything still debated is marked as such rather than presented as settled.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Common name; beta form often denoted beta-NMN |
| Chemical formula | C11H15N2O8P | As free acid; salt forms differ |
| Molar mass | 334.22 g/mol | Calculated for the free acid |
| CAS Registry Number | 1094-61-7 | For beta-nicotinamide mononucleotide |
| Biochemical role | NAD+ intermediate | Participates in the salvage biosynthesis pathway |
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
=== September === 1 September Kelly Ana Morey, novelist and poet (born 1968) Peter Truscott, cricketer (Canterbury, Wellington, national team) (born 1941). 2 September – David H. Clark, astrophysicist (Rutherford Appleton Laboratory) and science administrator (SERC, EPSRC). 4 September – Maxine Arnold, local politician, Porirua City Councillor (1974–1992), Wellington Regional Councillor (1980–1995), first women elected to a licensing trust (1968) (born 1928). 6 September – Dame Pat Harrison, educationalist and local politician, principal of Queen's High School, Dunedin (1975–1994), University of Otago council member (1983–1994), Otago Regional Councillor (born 1932). 7 September Robin Chadwick, actor (Julius Caesar, The Brothers) (born 1939). John Irwin, psychologist (University of Auckland) (born 1934). 8 September – Tom Phillips, fugitive father who disappeared with his three children between 2021 and 2025. 9 September David Buckingham, physical chemist (Australian National University, University of Otago), Fellow of the Royal Society of New Zealand (since 1980) (born 1936). Charlie Cotton, basketball player (national team) (born 1943). 10 September – Stan Martin, rugby league player (Richmond Rovers) and coach (Whitehaven, Cook Islands, women's national team) (born 1953). 11 September Randall Morton, otolaryngologist (University of Auckland) (born 1947). Graham Young, educator, principal of Tauranga Boys' College (1985–2008).
When used for analysis of mixtures, the eluant is usually collected in fractions of 1–5 ml which can be further analyzed. When used for protein purification there may be only two collection containers: one for the purified product and one for waste.
Progeria (also Hutchinson–Gilford syndrome or Hutchinson–Gilford progeroid syndrome; HGPS) is a type of progeroid syndrome. A single gene mutation is responsible for causing progeria. The affected gene, known as lamin A (LMNA), makes a protein necessary for holding the cell nucleus together. When this gene mutates, an abnormal form of lamin A protein called progerin is produced. Progeroid syndromes are a group of diseases that cause individuals to age faster than usual. People born with progeria typically live until their mid- to late-teens or early twenties. Severe cardiovascular complications usually develop by puberty, later on resulting in death.
== See also == Capillary electrophoresis–mass spectrometry Ion-mobility spectrometry–mass spectrometry Liquid chromatography–mass spectrometry Prolate trochoidal mass spectrometer Pyrolysis–gas chromatography–mass spectrometry
== Related preservation methods == Other methods have been in place for thousands of years to halt the decomposition of the body. Mummification used by the ancient Egyptians is a widely known method which involves the removal of body fluid and wrapping the body in linens. Prior to mummification, Egyptians would lay the body in a shallow pit in the desert and allow the sun to dehydrate the body. Formalin, an important solution to body preservation, was introduced in 1896 to help with body preservation. Soon to follow formalin, color-preserving embalming solutions were developed to preserve lifelike color and flexibility to aid in the study of the body. Paraffin impregnation was introduced in 1925, and the embedding of organs in plastic was developed in the 1960s. Body preservation methods current to the 21st century are cryopreservation, which involves the cooling of the body to very low temperatures to preserve the body tissues, plastination, and embalming. Other methods used in modern times include the Silicone S 10 Standard Procedure, the Cor-Tech Room temperature procedure, the Epoxy E 12 procedure, and the Polyester P 35 (P 40) procedure. The Silicone S 10 is the procedure most often used in plastination and creates opaque, natural-looking specimen., Dow Corning Corporation's Cor-Tech Room Temperature Procedure is designed to allow plastination of specimen at room temperature to various degrees of flexibility using three combinations of polymer, crosslinker, and catalyst.
Sources: en.wikipedia.org
=== Inreda AP === In collaboration with the Academic Medical Center in Amsterdam, Inreda Diabetic B.V. has developed a closed loop system with insulin and glucagon. The initiator, Robin Koops, started to develop the device in 2004 and ran the first tests on himself. In October 2016 Inreda Diabetic B.V. got the ISO 13485 license, a first requirement to produce its artificial pancreas. The product itself is called Inreda AP, and soon made some highly successful trials. After clinical trials, it received the CE marking, noting that it complies with European regulation, in February 2020. In October 2020 the health insurance company Menzis and Inreda Diabetic then started a pilot with 100 patients insured by Menzis. These are all patients that face very serious trouble in regulating their blood glucose levels. They now use the Inreda AP instead of the traditional treatment. Another large scale trial with the Inreda AP was set up in July 2021, and should determine whether Dutch health insurance should cover the device for all their insured. A smaller improved version of the Inreda AP is scheduled for release in 2023.
In 1939, at the Sir William Dunn School of Pathology at the University of Oxford, Ernst Boris Chain drew the attention of the professor in charge of the school, the Australian scientist Howard Florey, to Fleming's largely forgotten 1929 paper. They decided that the study of antibacterial substances produced by micro-organisms might be a fruitful avenue of research. Florey led an interdisciplinary research team that included Edward Abraham, Mary Ethel Florey, Arthur Duncan Gardner, Norman Heatley, Margaret Jennings, Jean Orr-Ewing and Gordon Sanders. Each member of the team tackled a particular aspect of the problem in their area of expertise, with simultaneous research along different lines building up a complete picture. This sort of collaboration was practically unknown in the United Kingdom at the time. Three sources were initially chosen for investigation: Bacillus subtilis, Trueperella pyogenes and penicillin. "[The possibility] that penicillin could have practical use in clinical medicine", Chain later recalled, "did not enter our minds when we started our work on penicillin." The broad subject area was deliberately chosen as one requiring long-term funding. Florey approached the Medical Research Council (MRC) for support in September 1939. The secretary of the council, Edward Mellanby authorized the project, allocating £250 (equivalent to £14,000 in 2025) to launch the project, with £300 for salaries (equivalent to £17,000 in 2025) and £100 for expenses (equivalent to £6,000 in 2025) per annum for three years.
=== ColdFusion Components (Objects) === ColdFusion was originally not an object-oriented programming language like PHP versions 3 and below. ColdFusion falls into the category of OO languages that do not support multiple inheritance (along with Java, Smalltalk, etc.). With the MX release (6+), ColdFusion introduced basic OO functionality with the component language construct which resembles classes in OO languages. Each component may contain any number of properties and methods. One component may also extend another (Inheritance). Components only support single inheritance. Object handling feature set and performance enhancing has occurred with subsequent releases. With the release of ColdFusion 8, Java-style interfaces are supported. ColdFusion components use the file extension cfc to differentiate them from ColdFusion templates (.cfm).
=== Apoptosis === Both internal and external signals can lead to the induction of apoptosis, or programmed cell death. The resulting deconstruction of cellular components is primarily carried out by specialized proteases known as caspases, but the proteasome also plays important and diverse roles in the apoptotic process. The involvement of the proteasome in this process is indicated by both the increase in protein ubiquitination, and of E1, E2, and E3 enzymes that is observed well in advance of apoptosis. During apoptosis, proteasomes localized to the nucleus have also been observed to translocate to outer membrane blebs characteristic of apoptosis. Proteasome inhibition has different effects on apoptosis induction in different cell types. In general, the proteasome is not required for apoptosis, although inhibiting it is pro-apoptotic in most cell types that have been studied. Apoptosis is mediated through disrupting the regulated degradation of pro-growth cell cycle proteins. However, some cell lines — in particular, primary cultures of quiescent and differentiated cells such as thymocytes and neurons — are prevented from undergoing apoptosis on exposure to proteasome inhibitors. The mechanism for this effect is not clear, but is hypothesized to be specific to cells in quiescent states, or to result from the differential activity of the pro-apoptotic kinase JNK. The ability of proteasome inhibitors to induce apoptosis in rapidly dividing cells has been exploited in several recently developed chemotherapy agents such as bortezomib and salinosporamide A.
Sources: en.wikipedia.org
Nicotinamide mononucleotide is a nucleotide intermediate in the biosynthesis of NAD+. It consists of nicotinamide attached to a ribose phosphate unit. NMN occurs naturally in cells and is present at low levels in some foods.
NMN is a direct precursor in the NAD+ salvage pathway. Enzymes called NMNAT convert NMN into NAD+, a coenzyme used in metabolism and cell signaling. Raising NMN may increase NAD+ in some experimental settings, but the effect depends on tissue and organism.
No. Nicotinamide riboside is a related compound that lacks the phosphate group present in NMN. Cells can convert nicotinamide riboside into NMN, and both compounds feed into NAD+ production through overlapping routes.
NMN stands for nicotinamide mononucleotide. It is a nucleotide intermediate in the cellular pathway that produces NAD+, a coenzyme involved in energy metabolism and signaling. NMN is not the same compound as NAD+.